Recently, MGI and Singapore biotechnology company MiRXES Pte Ltd. (MiRXES) officially reached a strategic partnership. MiRXES will create a leading genome research method based on MGI's DNBSEQ-T10×4RS ultra-high-throughput sequencing platform, aiming to promote the scientific research development and application of spatiotemporal omics and multi-omics technologies in the fields of human development and disease research.
Based on this cooperation, MiRXES will leverage its RNA end-to-end translational research capabilities and leading molecular diagnostic development capabilities, combined with the spatiotemporal omics Stereo-seq technology independently developed by Shenzhen BGI Life Sciences Research Institute. Based on MGI's leading DNBSEQ-T10×4RS sequencing platform, MiRXES will build an ultra-high-throughput, high-resolution spatiotemporal omics platform.
About MGI Tech Co., Ltd.
MGI Tech Co., Ltd. (referred to as MGI) is committed to building core tools and technology to lead life science through intelligent innovation. With a focus on R&D, production and sales of DNA sequencing instruments, reagents, and related products, MGI provides real-time, panoramic, and full-life-cycle equipment and systems for precision medicine, precision agriculture, precision healthcare and other relevant industries. MGI is a leading producer of clinical high-throughput gene sequencers, and its multi-omics platforms include genetic sequencing, medical imaging, and laboratory automation.
About MiRXES Pte Ltd.
We are a Singapore-headquartered biotechnology company focused on improving and saving lives with RNA-powered disease early detection tests.
Our story began in early 2000s when our founders pioneered a highly sensitive, specific and robust detection technology for microRNA (miRNA), the smallest genetic material ever found in human and other living organisms. Realizing the potential of miRNA-based clinical applications in solving unmet needs in cancer, cardiovascular, metabolic, and infectious diseases, we decided to bring our technology from lab to clinic.
We believe that the future of healthcare will shift from treating the sick to preventive healthcare. Our science and innovation will continue as we are committed to changing lives by delivering preventive healthcare solutions to all.
Copyright © 2024 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.